Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 October 2007, Vol. 110, No. 7, pp. 2667-2673.
Prepublished online as a Blood First Edition Paper on July 2, 2007; DOI 10.1182/blood-2005-11-026344.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2005-11-026344v1
110/7/2667    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawamata, N.
Right arrow Articles by Koeffler, H P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawamata, N.
Right arrow Articles by Koeffler, H P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted November 7, 2005
Accepted June 2, 2007

SAHA (vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells

Norihiko Kawamata*, John Chen, and H Phillip Koeffler

Division of Hematology/Oncology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, United States

* Corresponding author; email: kawamatan{at}cshs.org.

Mantle cell lymphoma (MCL) has a chromosomal translocation resulting in the expression of the cyclin D1 gene driven by the powerful enhancer of the immunoglobulin heavy chain gene leading to uncontrolled, overexpressed cyclin D1 protein. We showed that suberoylanilide hydroxamic acid (SAHA, vorinostat), one of the histone deacetylase (HDAC) inhibitors derived from hydroxamic acid, caused a dramatic decrease (90 %) in protein levels of cyclin D1 after 8 hours exposure to SAHA (5 µM) in MCL lines (SP49, SP53, Jeko1). Messenger RNA levels and protein stability of cyclin D1 were minimally affected by SAHA over 8 hours. In contrast, metabolic labeling assays showed that SAHA decreased incorporation of [35S]-methionine into cyclin D1 protein. The drug also decreased levels of phosphorylated Akt, mTOR, and eIF4E-BP and lowered the cap site binding activity of eIF4E in the MCL cells. In vitro phosphatidyl inositol (PI) kinase assay demonstrated that SAHA directly inhibited kinase activity of PI 3' kinase. Taken together, SAHA caused a rapid decrease of cyclin D1 in MCL by blocking the translation of cyclin D1 by inhibiting the PI3K/Akt/mTOR/eIF4E-BP pathway, probably by PI3K inhibition.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
O. A. O'Connor
Mantle Cell Lymphoma: Identifying Novel Molecular Targets in Growth and Survival Pathways
Hematology, January 1, 2007; 2007(1): 270 - 276.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020